To explore the clinical significance and correlation of SHMT2 and β-catenin in CRC, immunohistochemistry (IHC) analysis was used to validate the expression of SHMT2 and β-catenin by using a CRC tissue array that contained 85 human CRC tissues and corresponding normal adjacent tissues (NATs) (the clinical characteristics of patients are provided in Table S2). The gene discussed is SHMT2; the disease is colorectal carcinoma.